QL1706

Clinical trials for QL1706 explained in plain language.

Never miss a new study

Get alerted when new QL1706 trials appear

Sign up with your email to follow new studies for QL1706, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 3

New cocktail therapy targets tough liver cancer with blood clot

Disease control Recruiting now

This study tests a combination of an experimental immunotherapy (QL1706), a blood vessel blocker (bevacizumab), and chemotherapy given directly into the liver artery for people with advanced liver cancer that has caused a clot in the main portal vein. The goal is to see if this a…

Matched conditions: QL1706

Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control

Last updated Jun 27, 2026 08:10 UTC

QL1706

Get alerted when new QL1706 trials appear

New cocktail therapy targets tough liver cancer with blood clot